MiRNA detection methods and clinical implications in lung cancer

Future Oncology

Volumn 10, Issue 14, 2014, Pages 2279-2292

  Usó, Marta ^a   Jantus Lewintre, Eloisa ^a,b   Sirera, Rafael ^b   Bremnes, Roy M ^c   Camps, Carlos ^a,d  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^c UNIVERSITY OF TROMSØ   (Norway)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

biomarker; diagnosis; lung cancer; miRNA; miRNA profiling; prognosis

Indexed keywords

MICRORNA; TUMOR MARKER;

CANCER DIAGNOSIS; CELL LEVEL; GENE SEQUENCE; HUMAN; IN SITU HYBRIDIZATION; ISOLATION AND PURIFICATION; LUNG CANCER; MICROARRAY ANALYSIS; MULTICENTER STUDY (TOPIC); NEXT GENERATION SEQUENCING; NONHUMAN; QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SINGLE CELL LEVEL; GENETIC SCREENING; GENETICS; LUNG NEOPLASMS; PROCEDURES; STANDARDS;

GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 84916636025     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.93     Document Type: Review

References (82)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med. 359(13), 1367-1380 (2008).
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765-781 (2010).
4. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classifcation of malignant tumours. J. Thorac. Oncol. 2(8), 706-714 (2007).
5. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993).
6. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11(3), 228-234 (2009).
7. Lai EC. Micro RNAs are complementary to 3 UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet. 30(4), 363-364 (2002).
8. Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal microRNAs confer robustness to gene expression and have a signifcant impact on 3UTR evolution. Cell 123(6), 1133-1146 (2005).
9. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302(1), 1-12 (2007).
10. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24), 15524-15529 (2002).
11. Landi MT, Zhao Y, Rotunno M et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 16(2), 430-441 (2010).
12. Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 micro RNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64(11), 3753-3756 (2004).
13. Garofalo M, Di LG, Romano G et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16(6), 498-509 (2009).
14. Gallardo E, Navarro A, Vinolas N et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30(11), 1903-1909 (2009).
15. Lu J, Getz G, Miska EA et al. MicroRNA expression profles classify human cancers. Nature 435(7043), 834-838 (2005).
16. Xi Y, Nakajima G, Gavin E et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fxed paraffn-embedded samples. RNA 13 (10), 1668-1674 (2007).
17. Shen J, Jiang F. Applications of microRNAs in the diagnosis and prognosis of lung cancer. Expert. Opin. Med. Diagn. 6(3), 197-207 (2012).
18. Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fxed, paraffn-embedded tissues. J. Mol. Diagn. 10(3), 203-211 (2008).
19. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110(1), 13-21 (2008).
20. Ibberson D, Benes V, Muckenthaler MU, Castoldi M. RNA degradation compromises the reliability of microRNA expression profling. BMC Biotechnol. 9, 102 (2009).
21. Yin JQ, Zhao RC, Morris KV. Profling microRNA expression with microarrays. Trends Biotechnol. 26(2), 70-76 (2008).
22. Beuvink I, Kolb FA, Budach W et al. A novel microarray approach reveals new tissue-specifc signatures of known and predicted mammalian microRNAs. Nucleic Acids Res. 35(7), e52 (2007).
23. Raponi M, Dossey L, Jatkoe T et al. MicroRNA classifers for predicting prognosis of squamous cell lung cancer. Cancer Res. 69(14), 5776-5783 (2009).
24. Benes V, Castoldi M. Expression profling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 50(4), 244-249 (2010).
25. Dijkstra JR, Mekenkamp LJ, Teerenstra S, De Krijger I, Nagtegaal ID. MicroRNA expression in formalin-fxed paraffn embedded tissue using real time quantitative PCR: the strengths and pitfalls. J. Cell. Mol. Med. 16(4), 683-690 (2012).
26. Chen C, Ridzon DA, Broomer AJ et al. Real-time quantifcation of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33(20), e179 (2005).
27. Lao K, Xu NL, Yeung V, Chen C, Livak KJ, Straus NA. Multiplexing RT-PCR for the detection of multiple miRNA species in small samples. Biochem. Biophys. Res. Commun. 343(1), 85-89 (2006).
28. Mestdagh P, Feys T, Bernard N et al. High-throughput stem-loop RT-qPCR miRNA expression profling using minute amounts of input RNA Nucleic Acids Res. 36(21), e143 (2008).
29. Nolan T, Hands RE, Bustin SA. Quantifcation of mRNA using real-time RT-PCR. Nat. Protoc. 1(3), 1559-1582 (2006).
30. Zipper H, Brunner H, Bernhagen J, Vitzthum F. Investigations on DNA intercalation and surface binding by SYBR Green I, its structure determination and methodological implications. Nucleic Acids Res. 32(12), e103 (2004).
31. Mohammadian A, Mowla SJ, Elahi E, Tavallaei M, Nourani MR, Liang Y. Normalization of miRNA qPCR high-throughput data: a comparison of methods. Biotechnol. Lett. 35(6), 843-851 (2013).
32. Xie Y, Todd NW, Liu Z et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67(2), 170-176 (2010).
33. Yu SL, Chen HY, Chang GC et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13(1), 48-57 (2008).
34. Mascaux C, Laes JF, Anthoine G et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur. Respir. J. 33(2), 352-359 (2009).
35. Silva J, Garcia V, Zaballos A et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur. Respir. J. 37(3), 617-623 (2011).
36. Berghmans T, Ameye L, Willems L et al. Identifcation of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer 82(2), 340-345 (2013).
37. Hennessey PT, Sanford T, Choudhary A et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS ONE 7(2), e32307 (2012).
38. Skrzypski M, Czapiewski P, Goryca K et al. Prognostic value of miRNA expression in operable non-small cell lung cancer patients. Br. J. Cancer 110(4), 991-1000 (2014).
39. Cazzoli R, Buttitta F, Di NM et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J. Thorac. Oncol. 8(9), 1156-1162 (2013).
40. Rosenfeld N, Aharonov R, Meiri E et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 26(4), 462-469 (2008).
41. Boeri M, Verri C, Conte D et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl Acad. Sci. USA 108(9), 3713-3718 (2011).
42. Yu L, Todd NW, Xing L et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 127(12), 2870-2878 (2010).
43. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol. 23(8), 1157-1164 (2010).
44. Shen J, Todd NW, Zhang H et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 91(4), 579-587 (2011).
45. Campayo M, Navarro A, Vinolas N et al. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur. Respir. J. 41(5), 1172-1178 (2013).
46. Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang YK. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer 11, 393 (2011).
47. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J. Thorac. Oncol. 5(11), 1755-1763 (2010).
48. Chen Q, Si Q, Xiao S et al. Prognostic signifcance of serum miR-17-5p in lung cancer. Med. Oncol. 30(1), 353 (2013).
49. Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B. Circulating MicroRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. PLoS ONE 8(11), e81408 (2013).
50. Garofalo M, Romano G, Di LG et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and geftinib resistance in lung cancers. Nat. Med. 18(1), 74-82 (2012).
51. Romano G, Acunzo M, Garofalo M et al. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc. Natl Acad. Sci. USA 109(41), 16570-16575 (2012).
52. Kreil DP, Russell RR, Russell S. Microarray oligonucleotide probes. Methods Enzymol. 410, 73-98 (2006).
53. Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 9(10), 1274-1281 (2003).
54. Shingara J, Keiger K, Shelton J et al. An optimized isolation and labeling platform for accurate microRNA expression profling. RNA 11(9), 1461-1470 (2005).
55. Castoldi M, Schmidt S, Benes V et al. A sensitive array for microRNA expression profling (miChip) based on locked nucleic acids (LNA). RNA 12(5), 913-920 (2006).
56. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profling from low-input total. RNA 13(1), 151-159 (2007).
57. Davison TS, Johnson CD, Andruss BF. Analyzing micro-RNA expression using microarrays. Methods Enzymol. 411, 14-34 (2006).
58. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defnes cancer gene targets. Proc. Natl Acad. Sci. USA 103(7), 2257-2261 (2006).
59. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006).
60. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 70 (1), 36-45 (2010).
61. Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A. MicroRNA expression profles of whole blood in lung adenocarcinoma. PLoS ONE 7(9), e46045 (2012).
62. Roth C, Stuckrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H. Low levels of cell-free circulating miR-361-3p and miR-625∗ as blood-based markers for discriminating malignant from benign lung tumors. PLoS ONE 7(6), e38248 (2012).
63. Metzker ML. Sequencing technologies-the next generation. Nat. Rev. Genet. 11(1), 31-46 (2010).
64. Margulies M, Egholm M, Altman WE et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437(7057), 376-380 (2005).
65. Pritchard CC, Cheng HH, Tewari M. MicroRNA profling: approaches and considerations. Nat. Rev. Genet. 13(5), 358-369 (2012).
66. Beane J, Vick J, Schembri F et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev. Res. (Phila.) 4(6), 803-817 (2011).
67. Kalari KR, Rossell D, Necela BM et al. Deep sequence analysis of non-small cell lung cancer. Integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations. Front. Oncol. 2, 12 (2012).
68. Ju YS, Lee WC, Shin JY et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22(3), 436-445 (2012).
69. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum. a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008).
70. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identifed in a genome-wide serum microRNA expression profling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28(10), 1721-1726 (2010).
71. Keller A, Backes C, Leidinger P et al. Next-generation sequencing identifes novel micro RNAs in peripheral blood of lung cancer patients. Mol. Biosyst. 7(12), 3187-3199 (2011).
72. Meng W, Ye Z, Cui R et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin. Cancer Res. 19(19), 5423-5433 (2013).
73. Nuovo GJ. In situ detection of microRNAs in paraffn embedded, formalin fxed tissues and the co-localization of their putative targets. Methods 52(4), 307-315 (2010).
74. Jorgensen S, Baker A, Moller S, Nielsen BS. Robust one-day in situ hybridization protocol for detection of microRNAs in paraffn samples using LNA probes. Methods 52(4), 375-381 (2010).
75. Wang S, Aurora AB, Johnson BA et al. The endothelial-specifc microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15(2), 261-271 (2008).
76. Voortman J, Goto A, Mendiboure J et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res. 70(21), 8288-8298 (2010).
77. Nuovo GJ. In situ detection of precursor and mature microRNAs in paraffn embedded, formalin fxed tissues and cell preparations. Methods 44(1), 39-46 (2008).
78. Donnem T, Lonvik K, Eklo K et al. Independent and tissue-specifc prognostic impact of miR-126 in nonsmall cell lung cancer. coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 117(14), 3193-3200 (2011).
79. Donnem T, Eklo K, Berg T et al. Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J. Transl. Med. 9, 6 (2011).
80. Donnem T, Fenton CG, Lonvik K et al. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS ONE 7(1), e29671 (2012).
81. Eilertsen M, Andersen S, Al-Saad S et al. Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer 83(2), 272-278 (2014).
82. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5(7), 522-531 (2004).